Subcategory
General, Pancreatic cancer, Colorectal cancer, Non-small cell lung cancer (NSCLC)
Trial Type
other systemic therapies
Description for experts
The main purpose of this study is to assess safety & tolerability and antitumor activityof LY3962673 as monotherapy and in combination with other chemotherapy agents inparticipants with KRAS G12D-mutant advanced solid tumor types. The study is expected tolast approximately 5 years.
Description for laymen
The main purpose of this study is to assess safety & tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
JSON Data
{
"short_title": "Lilly J5J-OX-JZZA",
"data_mode": "900",
"data_mode_number": "000002424",
"official_title": "A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",
"accrual_state": "planned",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "not_applicable",
"ctgov_number": "NCT06586515",
"eudract_number": "2024-516440-25",
"general_contact_email": "ectu@ukdd.de",
"general_contact_phone": "+49 351-4587566",
"hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke",
"description_laie_de": "Der Hauptzweck dieser Studie besteht darin, die Sicherheit und Vertr\u00e4glichkeit sowie die Antitumoraktivit\u00e4t von LY3962673 als Monotherapie und in Kombination mit anderen Chemotherapeutika bei Teilnehmern mit KRAS G12D-mutierten fortgeschrittenen soliden Tumorarten zu untersuchen. Die Studie wird voraussichtlich etwa 5 Jahre dauern.",
"description_laie_en": "The main purpose of this study is to assess safety & tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.",
"description_expert_de": "Der Hauptzweck dieser Studie besteht darin, die Sicherheit und Vertr\u00e4glichkeit sowie die Antitumoraktivit\u00e4t von LY3962673 als Monotherapie und in Kombination mit anderen Chemotherapeutika bei Teilnehmern mit KRAS G12D-mutierten fortgeschrittenen soliden Tumorarten zu untersuchen. Die Studie wird voraussichtlich etwa 5 Jahre dauern.",
"description_expert_en": "The main purpose of this study is to assess safety & tolerability and antitumor activityof LY3962673 as monotherapy and in combination with other chemotherapy agents inparticipants with KRAS G12D-mutant advanced solid tumor types. The study is expected tolast approximately 5 years.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "I",
"main_cat_id": 10,
"sub_cat_id": 50
}
